Weigao Group (01066) will distribute a final dividend of HK$0.1035 per share on July 12th.
Weigao Group (01066) announced that it will distribute a year-end dividend of HKD 0.1035 per share as of December 31, 2023 on July 12, 2024.
Private Companies Among Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Largest Stockholders and Were Hit After Last Week's 6.4% Price Drop
Key Insights Significant control over Shandong Weigao Group Medical Polymer by private companies implies that the general public has more power to influence management and governance-related decisions
Shandong Weigao Group Medical Polymer Sets Dividend Payment Date
Shandong Weigao Group Medical Polymer (HKG:1066) will pay the 0.0943 yuan per share final dividend for 2023 following shareholders' approval, according to a Tuesday filing with the Hong Kong Exchange.
Shandong Weigao Group's Successful AGM Outcomes
Shandong Weigao Group Announces Board Structure
Weigao Co., Ltd. (01066.HK): Plans to pay 2023 final interest of $0.0943 per share
Gelonghui, May 28 | Weigao Co., Ltd. (01066.HK) announced that the company will distribute a final pre-tax dividend of RMB 0.0943 per share for the year ended December 31, 2023 to all shareholders included in the company's shareholder register on June 11, 2024. According to the company's articles of association, dividends will be declared in RMB as the currency unit and in RMB. The “full circulation” dividends of Hong Kong Stock Connect and H shares will be paid in RMB, while other H share dividends will be paid in Hong Kong dollars. The company's dividend per H share before tax (i.e. RMB 0.0943) will be HK$0.1035. The company has appointed Bank of China (
Weigao Co., Ltd. (01066): Wang Daoming appointed as Executive Director
Weigao Co., Ltd. (01066) issued an announcement. After the annual general meeting of shareholders, Mr. Wang Daoming (Mr. Wang) has been appointed...
WEIGAO GROUP: POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 28 MAY 2024 APPOINTMENT OF DIRECTORS AMENDMENT OF THE ARTICLES OF ASSOCIATION AND PAYMENT OF FINAL DIVIDEND
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon
With a median price-to-earnings (or "P/E") ratio of close to 10x in Hong Kong, you could be forgiven for feeling indifferent about Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) P
Weigao Co., Ltd. (01066): Weigao Orthopedic (688161.SH)'s net profit of 34.9057 million yuan in the first quarter decreased by 62.92% year-on-year
Weigao Co., Ltd. (01066) announced Weigao Orthopedic (688161.SH) results for the first quarter of 2024, business...
威高股份:2023年報
These 4 Measures Indicate That Shandong Weigao Group Medical Polymer (HKG:1066) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
From the pain of collection to the decline in net profit distribution, going overseas or becoming the only way out for orthopedic consumables?
As the fourth batch of high-value consumables collected last year directly targeted artificial lenses and high-value orthopedic sports medicine consumables, almost all high-value consumables in the orthopedic field have already been collected. Even if this collection is “mild” compared to the previous three rounds of overall price cuts, it will inevitably have a negative impact on the performance of leading domestic companies in the short term, and there is a certain relationship with the imbalance in the companies' “price for volume” game. Judging from the 2023 financial reports disclosed by many industry companies, the traditional logic of “price for volume” collection has not been fully demonstrated. It is not that the more companies that win the bid, the better their performance growth. On the contrary, the increase in sales brought about by harvesting does not seem to offset the product
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Cormedix (CRMD)
Bank Rating | DBS: Lowering the target price of Weigao shares to HK$6.4 to maintain a “buy” rating
According to a research report published by DBS, the profit of Weigao shares fell 27.6% year-on-year in 2023, in line with the profit announcement issued earlier, mainly due to falling prices of medical devices and consumables products in different businesses due to volume procurement policies, and no longer selling products related to the epidemic. Accordingly, DBS lowered Weigao's profit forecast for 2024 to 2025 by 32% and 35%, and the target price was lowered from HK$11.6 to HK$6.4. However, the bank pointed out that Weigao's stock price has fallen 37% a few years ago. The expected negative factors are fully reflected in the stock price performance. It is optimistic that the company is the leading supplier of medical consumables and pharmaceutical packaging in China
Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
With its stock down 36% over the past three months, it is easy to disregard Shandong Weigao Group Medical Polymer (HKG:1066). But if you pay close attention, you might find that its key financial in
Changes in Hong Kong stocks | Medical device stocks rose higher in the afternoon, and mining affected the industry's high-value consumables business growth expectations this year generally improved
Medical device stocks rose in the afternoon. As of press release, Weigao shares (01066) rose 9.25% to HK$5.08; Elken Healthcare (01,789) rose 4.35% to HK$4.08; and minimally invasive robot-B (02252) rose 1.91% to HK$13.88.
Weigao Group Logs 28% Decline in 2023 Profit
Shandong Weigao Group Medical Polymer (HKG:1066) recorded a 27.6% decline in attributable profit for the year ended Dec. 31, 2023, to 2 billion yuan from 2.76 billion yuan in 2022, a Tuesday filing on
Weigao shares (01066) will pay a final dividend of $0.0943 per share on July 12
Weigao Co., Ltd. (01066) announced that the company will pay a final dividend per share on July 12, 2024...
No Data